Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

2 mins

Greatest Hits of 2024

touchIMMUNOLOGY
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 18th 2024
greatest content of 2024

Join us as we unveil the content that made the greatest impact in 2024.

As 2024 comes to a close, we want to take a moment to thank everyone who joined our touchIMMUNOLOGY community this year. It’s been an honor to connect with so many leading experts across various fields and to continue collaborating with our medical society partners to deliver high-quality, easily accessible content.

From insightful Q&As and news articles to engaging podcasts, conference highlights, and medical education resources, this year has been filled with valuable content designed to support your daily practice and, ultimately, enhance patient care.

Here are just a few of our standout moments from 2024.


Most read article:

CAR T cell therapy: A new hope for refractory lupus?

This review discusses CAR T cell therapy, comparing it with established B cell depletion therapies, and exploring its safety, limitations and promise in the management of patients with systemic lupus erythematosus (SLE).

 


Most watched video:

A patient’s perspective – Journey to diagnosis of seronegative rheumatoid arthritis

 

Ailsa Bosworth, Founder and National Patient Champion for the National Rheumatoid Arthritis Society (NRAS), reviews her personal journal to, and following, diagnosis of seronegative RA and the challenges she has faced along the way.

 

 


Most listened to podcast:

JAK inhibitors: A new player for hard-to-treat skin conditions

Dr. Bill Damsky, MD, joins us to discuss the impact JAK inhibitors have on tackling a wide range of skin conditions. We explore their journey from proof-of-concept to becoming a treatment option for traditionally hard-to-treat and rare conditions, touch on the ongoing safety debate, and highlight their future impact.

 


Most viewed news story:

www.touchimmunology.com

New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis

This article reports on the promising phase 3 clinical trial results for cendakimab (CEN), a monoclonal antibody targeting interleukin (IL)-13, and its impact on the symptoms, as well as the histologic and endoscopic features, of eosinophilic oesophagitis.

 

 

 

 


Stay informed in 2025 – sign up for our newsletter and get the latest content delivered directly to your inbox.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup